We use cookies for analytics and ads to improve your experience. You can accept or decline. See our Privacy Policy.
Unlisted shares are illiquid and carry higher risk than listed securities. Prices are indicative, not live. Read the risk disclosure.
52-Week Range
Valuation
Investment Thesis
Gynofem Healthcare and Pharmaceuticals Limited is an early-stage women's health pharmaceutical company with a focused and growing niche. While the sector has strong fundamentals, the company is very young (2022), unlisted, and lacks a public track record. Investment carries significant startup risk but also meaningful upside if the company successfully builds its brand and distribution in the women's health pharma space.
Pros
Cons
Business Segments
Gynecology Pharma (Drug Formulation)
Drug formulation and development focused on women's health / gynecology pharmaceutical products.
Revenue Model
Prescription-led pharma revenue model through medical representative (MR) network calling on gynaecologists, obstetricians, and general physicians. Revenue from branded generic formulations sold through pharmaceutical distributors and retail chemists.
Detailed Analysis
Growth Plans
India's National Women's Health Mission increasing awareness and demand for women's healthcare products
Growing middle-class female consumers investing in preventive and specialized healthcare
Government schemes for maternal and child health driving volume in nutritional and reproductive health products
Indore pharma cluster provides cost-effective manufacturing and regulatory support
Industry Tailwinds
Recent Developments
Company in early operational phase post-incorporation in 2022, establishing its product portfolio, distribution network, and medical representative force for gynecological pharma segment.
2024Indore's status as a major pharma manufacturing hub with contract manufacturing organizations (CMOs), API suppliers, and regulatory expertise provides favorable conditions for early-stage pharma companies.
2023Comparable Companies
MANKIND · ~₹90,000 Cr
ABBOTINDIA · ~₹45,000 Cr
Frequently Asked Questions
About Gynofem Healthcare and Pharmaceuticals Limited
Gynofem Healthcare and Pharmaceuticals Limited is an Indore, Madhya Pradesh-based pharmaceutical company incorporated on 13 October 2022, specialising in women's healthcare and gynaecological drug development. With CIN U24290MP2022PLC063077, the company was founded by Nishi Kant Joshi, Anurag Mendhe, and Kartikay Joshi to address the underserved segment of women's health pharmaceuticals in India. The company has an authorised capital of Rs 10 crore and paid-up capital of Rs 9.92 crore. Financial performance shows a contrasting picture: net profit grew 190.59% while total revenue declined 6.49%, suggesting improved efficiency despite revenue challenges. The company is focused on developing proprietary formulations for gynaecological conditions, hormonal therapies, fertility drugs, and related women's health products. India's women's healthcare market is growing rapidly, driven by increasing health awareness, rising female workforce participation, and improving access to specialised medical care. Gynofem Healthcare positions itself to capture this growth in an underpenetrated pharmaceutical niche. The Indore location in Madhya Pradesh provides access to the pharmaceutical manufacturing hub in central India.
Key Milestones
Incorporated December 13, 2022 in Indore, Madhya Pradesh (CIN: U24290MP2022PLC063077)
ISIN INE0NLL01017; gynecology/women's health drug formulation; authorized ₹10 Cr, paid-up ₹9.92 Cr
Common questions about unlisted shares
You buy from and sell to the wisefolio desk — shares route through the desk's demat, money-in before shares-out.
You enquire
· Takes 2 minutesTell us the company and quantity you want. Share your demat details so we can settle directly into your account.
We source & quote
· Typically within 1 business dayOur desk sources the shares and comes back with a firm price and an allocation for the quantity available.
You accept the allocation
· Quote valid for 3 daysReview the price, quantity and total. Accept to lock the allocation. The quote is valid for a short window before it needs re-pricing.
You transfer the funds
· Pay within 2 days of acceptingPay by direct bank transfer to the desk's published account — never to a personal account. We confirm receipt and begin the transfer.
Shares reach your demat
· Usually credited within 2–3 business daysOnce payment is verified, the shares are transferred from the desk's demat into yours, and you receive a transfer confirmation.
A principal desk for unlisted & pre-IPO shares — you transact with us, not a stranger.
You enquire
Takes 2 minutes
We source & quote
Typically within 1 business day
You accept the allocation
Quote valid for 3 days
You transfer the funds
Pay within 2 days of accepting
Shares reach your demat
Usually credited within 2–3 business days
Unlisted shares are illiquid and carry higher risk. Pricing is indicative, not live, and these are private off-market transactions with no exchange settlement guarantee. Read the full risk disclosure.
Be the first to discuss Gynofem Healthcare and Pharmaceuticals Limited — share your research, ask questions, or compare notes with other investors.
India's National Women's Health Mission increasing awareness and demand for women's healthcare products
Growing middle-class female consumers investing in preventive and specialized healthcare
Government schemes for maternal and child health driving volume in nutritional and reproductive health products
Indore pharma cluster provides cost-effective manufacturing and regulatory support
Industry Headwinds
High competition from large established pharma brands in women's health space
Significant capital requirements to build brand and salesforce before achieving profitability
Regulatory challenges in getting new formulations approved by CDSCO
Limited management track record as a newly incorporated entity
Company was incorporated in 2022 with no established track record. High failure rate among early-stage pharmaceutical companies.
Source: Media Reports / Public Records
Competing against well-established women's health pharma brands from Mankind Pharma, Abbott India, Sun Pharma, Cipla, and Bayer. Doctor-prescribing habits are deeply entrenched.
Source: Media Reports / Public Records
Pharmaceutical manufacturing requires CDSCO approvals, WHO-GMP certification, and ongoing compliance with Schedule M. Non-compliance can lead to manufacturing ban.
Source: Regulatory Filings
Pharma distribution involves long credit cycles to distributors and stockists. Early-stage companies face significant working capital stress.
Source: AlphaHub Research
Building a skilled medical representative and field sales force in the women's health specialty segment is expensive and time-consuming.
Source: Media Reports / Public Records
Company was incorporated in 2022 with no established track record. High failure rate among early-stage pharmaceutical companies.
Competing against well-established women's health pharma brands from Mankind Pharma, Abbott India, Sun Pharma, Cipla, and Bayer. Doctor-prescribing habits are deeply entrenched.
Pharmaceutical manufacturing requires CDSCO approvals, WHO-GMP certification, and ongoing compliance with Schedule M. Non-compliance can lead to manufacturing ban.
Pharma distribution involves long credit cycles to distributors and stockists. Early-stage companies face significant working capital stress.
Building a skilled medical representative and field sales force in the women's health specialty segment is expensive and time-consuming.
Joshi family management; early-stage company with no confirmed revenue history
